Compare DBCA & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DBCA | CYRX |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.3M | 419.3M |
| IPO Year | 2026 | 2008 |
| Metric | DBCA | CYRX |
|---|---|---|
| Price | $9.97 | $15.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.31 |
| AVG Volume (30 Days) | 40.5K | ★ 747.6K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.83 | $6.69 |
| 52 Week High | $10.07 | $16.89 |
| Indicator | DBCA | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 48.83 |
| Support Level | $9.83 | $14.51 |
| Resistance Level | $10.05 | $16.76 |
| Average True Range (ATR) | 0.02 | 0.80 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 40.09 |
D Boral Acquisition I Corp is a blank check company. It is formed as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.